Alto Neuroscience, Inc.
A clinical-stage biopharmaceutical company working in precision psychiatry, Alto Neuroscience uses brain imaging and biomarkers to match people with mental health treatments likely to work for them, rather than the usual trial-and-error approach. It was founded in 2019 by Dr. Amit Etkin, a psychiatrist and neuroscientist and former Stanford professor, building on his years of research. A naming quirk: "Alto" may nod to the Latin for "high" — and to Palo Alto, where Etkin worked at the VA medical center.
Bought 600.0K
Granted 34.7K · Bought 3.1K
Bought 32.0K
Granted 19.2K · Bought 7.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Chimera Investment LLC +3 co-filers10% owner · 3 transactions | — | 1.96Mas of Feb 2024 | — | 600.0K | — |
| Angermayer Christian +2 co-filersSee Remarks · 2 transactions | — | 926.5Kas of Feb 2024 | — | — | — |
| Etkin AmitPRESIDENT AND CEO, Director · 5 transactions | — | 833.9K | 34.7K | 3.1K | — |
| Cox Christopher NixonDirector · 2 transactions | — | 588.9Kas of Feb 2024 | — | — | — |
| Savitz AdamCHIEF MEDICAL OFFICER · 5 transactions | — | 39.9Kas of Jul 2024 | — | 32.0K | — |
| Chen Po Yu (Jeff)Director · 2 transactions | — | 39.3Kas of Feb 2024 | — | — | — |
| Smith Nicholas ConradCHIEF FINANCIAL OFFICER & CBO · 5 transactions | — | 24.1K | 19.2K | 7.7K | — |
| York GwillDirector · 1 transaction | — | 23.9Kas of Feb 2024 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +642.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.